PRADAXA® (CAPSULE)

Drug Information Related Patent

Hold Company

BOEHRINGER INGELHEIM

Learn More

Dosage and Administration

CAPSULE;ORAL

Specification

EQ 75MG BASE; EQ 150MG BASE; EQ 110MG BASE

Indication

PRADAXA® applies to reduce adult stroke in patients with nonvalvular atrial fibrillation and the risk of systemic embolism, reduce the adult patients with deep vein thrombosis and pulmonary embolism risk of recurrence, adult hip replacement, prevention of deep vein thrombosis and pulmonary embolism after the treatment of pediatric patients with venous thromboembolism events, reduce the risk of recurrence of pediatric patients with venous thromboembolism events.

Use

Instructions for Use

API

DABIGATRAN ETEXILATE MESYLATE

API Structure

We Supply

DABIGATRAN ETEXILATE MESYLATE

Note:

In-house Standard
Facility GMP
DMF/CDE/USMF

null

Note:

null

Note:

null

Drug Patent

Patent No	Expiration Date
7932273	2025/9/7
7932273*PED	2026/3/7
9034822*PED	2031/7/20
9034822	2031/1/20
7866474	2027/8/31
7866474*PED	2028/3/2

API Patent

Patent No	Expiration Date
7932273	2025/9/7
7932273*PED	2026/3/7

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION